While the government is looking at approving Covaxin for those between 2-18, experts advise exercising caution amidst a lack of choices and data for healthy kids before they return to school. Virologist Dr. Gagandeep Kang and Dr. Anand Pillai, Assistant Professor, Global Institute of Public Health, Ananthapuri Hospitals and Research Institute, Trivandrum, discuss the issue. Credits: T-Series, Maithri Manthan, India Today, WHO, WION, Shubham Jha.
See omnystudio.com/listener for privacy information.